Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Genetic Analyzer Enhancement

By Drug Discovery Trends Editor | September 25, 2012

Pacific Biosciences of California Inc. provider of the PacBio RS High Resolution Genetic Analyzer, announced the launch of the MagBead Station for the PacBio RS, a product enhancement that delivers more high-value long reads, enables use of small sample amounts, and makes sample preparation more robust.

The MagBead Station upgrade and associated MagBead kit enable sequencing of longer templates, especially for samples that are biologically difficult to prepare. This results in more 4-10 kilobase long reads captured with each SMRT Cell. Because the process is more robust, sequencing results have higher overall consistency. It also significantly reduces the amount of the input sample required, which can be critical for experiments when there is a small amount of useable DNA available from a sample.

The MagBead Station greatly reduces any adapter-dimer that may be present in some libraries and there are clearly benefits in terms of how much library is consumed during loading a sequencing run. Compared to diffusion loading, approximately one-tenth the library is needed to load each SMRT Cell, allowing much deeper sequence coverage from a single library preparation.

With this latest enhancement, users will be able to generate 10 kilobase-size libraries using as little as one microgram of sample, a five to 10-fold improvement from a few months ago. The MagBead Station will make a substantial difference in customers’ ability to run experiments on challenging samples because it will reduce the impact of the variability in sample prep while reducing the amount of sample needed to perform highly accurate sequencing.

Pacific Biosciences


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50